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Abstract
Background: Low transsphincteric fistulas less than 1/3 of the sphincter complex are easy to treat by fistulotomy
with a high success rate. High transsphincteric fistulas remain a surgical challenge. Various surgical procedures are
available, but recurrence rates of these techniques are disappointingly high. The mucosal flap advancement is
considered the gold standard for the treatment of high perianal fistula of cryptoglandular origin by most colorectal
surgeons. In the literature a recurrence rate between 0 and 63% is reported for the mucosal flap advancement.
Recently Armstrong and colleagues reported on a new biologic anal fistula plug, a bioabsorbable xenograft made
of lyophilized porcine intestinal submucosa. Their prospective series of 15 patients with high perianal fistula
treated with the anal fistula plug showed promising results.
The anal fistula plug trial is designed to compare the anal fistula plug with the mucosal flap advancement in the
treatment of high perianal fistula in terms of success rate, continence, postoperative pain, and quality of life.
Methods/design: The PLUG trial is a randomized controlled multicenter trial. Sixty patients with high perianal
fistulas of cryptoglandular origin will be randomized to either the fistula plug or the mucosal advancement flap.
Study parameters will be anorectal fistula closure-rate, continence, post-operative pain, and quality of life. Patients
will be followed-up at two weeks, four weeks, and 16 weeks. At the final follow-up closure rate is determined by
clinical examination by a surgeon blinded for the intervention.
Discussion: Before broadly implementing the anal fistula plug results of randomized trials using the plug should
be awaited. This randomized controlled trial comparing the anal fistula plug and the mucosal advancement flap
should provide evidence regarding the effectiveness of the anal fistula plug in the treatment of high perianal fistulas.
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Background
A perianal fistula is a common condition. It has an inci-
dence of 5.6 per 100.000 in women and 12.3 per 100.000
in men [1]. The disease occurs predominantly in the third
and fourth decade of life [2]. It is believed that infection
of the intersphincteric glands is the initiating event in fis-
tula in ano, in a process known as the 'cryptoglandular
hypothesis' [3].
Parks et al. [4] developed a classification system in which
fistula are divided into intersphincteric fistula, trans-
sphincteric fistula, suprasphincteric fistula and extras-
phincteric fistula. However the type of treatment depends
not on the location of the fistula tract but of the level of
the internal opening in the anal canal.
Low transsphincteric fistulas comprising less than 1/3 of
the external sphincter complex are easy to treat by fistulot-
omy with a high success rate. High transsphincteric fistu-
las remain a surgical challenge. Surgical procedures
include advancement flaps, loose-seton placement, and
the installation of fibrin glue. All of these techniques have
disappointing success rates. In the literature a recurrence
rate between 0 and 63% is reported for the mucosal flap
advancement [5-7]. Recently, Van der Hagen et al. [6] pub-
lished the result of 41 patients with high transsphincteric,
suprasphincteric and extrasphincteric fistula treated with
a mucosal flap advancement. The success rate was a mere
37% (with a median follow-up of 72 months).
The fibrin glue is an alternative to the mucosal advance-
ment flap, however long-term closure rates are low [8-14].
The percentages being as low as 16 percent. The liquid
consistency of fibrin glue is possibly not ideal for the pur-
pose of closing anorectal fistulas, because the glue is easily
extruded from the fistula tract by increased pressure [15].
Armstrong and colleagues reported a new biologic anal
fistula plug [16]. The plug is a FDA and CE approved bio-
absorbable xenograft, made of lyophilized porcine intes-
tinal submucosa by Cook Surgical, Inc., Bloomington, IN.
The material has inherent resistance to infection, pro-
duces no foreign body or giant cell reaction, and becomes
repopulated with host cell tissue during a period of three
months. The material was fashioned into a conical plug
and secured into the primary opening of the fistula tract.
Armstrong achieved promising results in a prospective
series of 15 patients treated with the anal fistula plug.
They compared the results with ten patients using fibrin
glue. Patients with high anorectal fistulas (high trans-
sphincteric or deeper) were included. Excluded were
patients with Crohn's disease or superficial fistulas (low
transsphincteric or more superficial). At a median follow-
up of 13.8 ± 3.1 weeks they achieved a significant better
fistula closure rate of 87% compared to the fibrin glue
group (P < 0.05).
These results call for a prospective randomised controlled
trial. Since mucosal flap advancement is the preferred
treatment for high cryptoglandular perianal fistula, the
anal fistula plug will be compared with mucosal flap
advancement in a randomised setting.
Methods/design
Study objectives
The objective of this study is to compare, in a prospective
randomized way, the anal fistula plug with the mucosal
advancement flap in the treatment of high transphincteric
perianal fistula in terms of fistula closure rate, continence,
morbidity, postoperative pain, and quality of life.
Study design
The PLUG trial is a prospective double blinded rand-
omized multicenter trial. Patients with high perianal fistu-
las of cryptoglandular origin will be randomized to either
the fistula plug or the mucosal advancement flap. Rand-
omization will be performed during surgery after finding
the internal opening. The computer randomization will
be done centrally in the Academic Medical Centre in
Amsterdam, the Netherlands. Stratification is performed
for the randomizing centers.
Patients will be blinded for the type of intervention i.e.
anal fistula plug or mucosal advancement flap. Patients
are followed-up at two weeks, four weeks, and 16 weeks.
At the final follow-up closure rate is determined by clini-
cal examination. Follow-up is done by a colorectal sur-
geon, who is blinded for the type of intervention. The
fistula will be rated closed if the external and the internal
opening are closed and no discharge is experienced. Oth-
erwise it is considered as a persistent fistula.
Study population
The study population consists of patients with high peri-
anal fistulas.
Inclusion criteria are; age above 18 years, high anorectal
fistula of cryptoglandular origin (transsphincteric, upper
2/3 of the sphinctercomplex which is confined by the
puborectal sling and the end of the anal canal), and
informed consent.
Exclusion criteria are; no internal opening found during
surgery, HIV-positive patients, Crohn's disease, malignant
cause, tuberculosis, hydradenitis suppurativa, and piloni-
dal sinus disease.BMC Surgery 2008, 8:11 http://www.biomedcentral.com/1471-2482/8/11
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Primary and secondary endpoints
The primary endpoints of the PLUG trial are fistula clo-
sure rate and continence. Continence will be evaluated
pre- and postoperatively using the COREFO, the Wexner
and the Vaizey score. The COREFO questionnaire has 27
questions to asses colorectal functional outcome [17]. The
Vaizey scale consists of three items about the type (gas,
fluid, solid) and frequency of incontinence (all scored
from zero to four) and four additional items that address
alteration in lifestyle (zero to four), the need to wear a pad
or plug (zero or two), the use of constipating medication
(zero or two), and the lack of ability to defer defecation
for 15 minutes (zero or four). The total score on the
Vaizey scale ranges from 0 (complete continence) to 24
(complete incontinence) [18].
Secondary endpoints are morbidity, postoperative pain,
and quality of life. Postoperatively patients will be asked
to grade their pain on a visual analogue scale (VAS: 0, no
pain; 10, worst imaginable pain) on different moments
during the follow-up. Quality of life will be evaluated
using the SF-36 questionnaire. The SF-36 measures eight
health attributes: physical functioning, social functioning,
role limitations due to physical problems, role limitations
due to emotional problems, mental health, pain, vitality
and general health perception. The higher the score, the
better the health rating with 100 points as the maximum
for each concept. In addition the EQ-5D questionnaire is
used.
Participating centers
Six Dutch hospitals, including one academic and five non-
academic hospitals, will enrol patients.
Ethics
The study is conducted in accordance with the principles
of the Declaration of Helsinki and 'good clinical practice'
guidelines. The protocol has been approved by the Medi-
cal Ethics Committee of the Academic Medical Centre in
Amsterdam and the local Ethical Committees of the par-
ticipating centers. Prior the randomization informed con-
sent will be obtained from all patients.
Study outline
Patients presenting in the outpatients department with
high perianal fistulas of cryptoglandular origin will be
asked for informed consent when the patient fulfils in-
and exclusion criteria.
Positioning of the anal fistula plug will be done according
to the instructions of Cook SIS technology. The plug is
fabricated from Surgisis (Cook Surgical, Inc., Blooming-
ton, IN), a bioabsorbable xenograft, made of lyophilized
porcine intestinal submucosa. The material has inherent
resistance to infection, produces no foreign body or giant
cell reaction, and becomes repopulated with host cell tis-
sue during a period of three months. All procedures will
be performed under general or locoregional anaesthesia.
Prophylactic broad-spectrum antibiotics will be adminis-
tered before surgery. During surgery the internal fistula
tract opening will be identified, followed by cleaning and
debriding the fistula tract with hydrogen peroxide. A
suture will be attached to the tail of the plug. A probe is
inserted into the external opening exiting through the
internal opening and the suture attached to the tail of the
plug is grasped. Then the plug is pulled into the fistula
tract, tail first. The suture is drawn into the tract until the
plug securely blocks the internal opening and fits snugly
within the tract. Any remaining portion of the plug that is
not implanted in the tract is trimmed and discarded. The
internal end of the plug is sutured in place with at least
two sutures. The internal sutures should close the anal
canal opening. In contrast with former instructions, no
external fixation suture is placed. The external opening is
left open to allow for drainage of the tract. In case of a
wide fistula tract, a second fistula plug can be put in place.
The rectal advancement flap was done according to the
following technique. The internal opening was excised
followed by mobilization of the mucosa, submucosa, and
a small amount of muscular fibers from the internal
sphincter complex. A rectal flap with a 2 to 3 cm broad
base was mobilized. The rectal flap was mobilized suffi-
ciently to cover the internal opening with overlap.
Hemostasis was performed to prevent a hematoma under
the flap. The fistula tract was curetted. The internal open-
ing was not closed before advancing the flap over the
internal opening. Finally the flap was sutured in the distal
anal canal.
Statistical analysis
Intention to treat
The analysis will be performed in accordance with the
intention to treat principle.
Sample size calculation
A success percentage of 87% was reported by Armstrong
and colleagues for the anal fistula plug [16]. For the
mucosal advancement flap a success percentage of 37%
was reported recently by Hagen and colleagues in a series
of 41 patients with a follow-up of 72 months [6].
To detect an increase in success percentage from 40% to
80%, using a significance level of 0.05, at least 46 patients
have to be randomized to achieve a power of 80%. In
total, 60 patients will be randomized.
Data collection and monitoring
Data are collected via datasheets on paper, which are sent
to the Academic Medical Centre by mail. PostoperativelyBMC Surgery 2008, 8:11 http://www.biomedcentral.com/1471-2482/8/11
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questionnaires on pain are filled in by patients. Sixteen
weeks after surgery questionnaires are sent to the patients
to assess continence and quality of life.
There will be regular contact between the study coordina-
tors and the participating centers. One research fellow will
monitor the included data of every patient.
Discussion
The main objective in the treatment of perianal fistula is
the healing of the fistula by closing the internal opening
while preserving the anal continence. Submucosal, inter-
sphincteric, and low transsphincteric fistulas, in the lower
one-third of the external sphincter complex are easy to
treat by simple fistulotomy, with a favourable success rate
and relatively little impact on faecal continence [19,20].
The surgical treatment of high perianal fistulas of cryptog-
landular origin in relation to morbidity remains a difficult
problem. The anal fistula plug appears to be a promising
alternative to the current treatment options for high peri-
anal fistulas [20-24]. The anal fistula plug is fabricated
from porcine collagen which stimulates tissue remodel-
ling leading to full closure the fistulous tract. Further-
more, the advantage of the plug is that it can be used
repeatedly, without risk of damaging the anal sphincter.
In a recent study describing the results of the surgical treat-
ment of perianal fistulas of cryptoglandular origin soiling
was reported following surgery in 40% of the patients
[25]. In these series 109 patients were treated by fistulot-
omy for low perianal fistulas. A rectal advancement flap
was performed in 70 patients for high transsphincteric fis-
tulas. Another advantage is that installing the plug is min-
imally invasive with possibly less postoperative pain.
During mucosal flap advancement, the fistula tract is
excised externally to the anal sphincter in order to ensure
an optimal drainage.
Before broadly implementing the anal fistula plug results
of randomized trials using the plug should be awaited.
This randomized controlled trial comparing the anal fis-
tula plug and the mucosal advancement flap should pro-
vide evidence regarding the effectiveness of the anal fistula
plug in the treatment of high perianal fistulas.
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